Neurons expressing melatonin receptor 1B (MTNR1B), also known as the MT2 melatonin receptor, represent a key component of the melatonin signaling system in the brain. MTNR1B is a G protein-coupled receptor (GPCR) that binds melatonin with high affinity, playing crucial roles in circadian rhythm regulation, sleep-wake cycles, and metabolic homeostasis. These neurons are distributed across several brain regions and peripheral tissues, where they mediate melatonin's effects on circadian entrainment, glucose metabolism, and neuroprotection.
MTNR1B-expressing neurons are found in several key locations:
-
Suprachiasmatic nucleus (SCN): The master circadian clock contains MTNR1B neurons that help synchronize circadian rhythms with the light-dark cycle. Melatonin acting through MT2 receptors in the SCN helps phase-shift circadian rhythms.
-
Retina: MTNR1B is expressed in retinal neurons, where it contributes to phototransduction and circadian visual processing.
-
Hypothalamus: MTNR1B neurons in hypothalamic regions regulate metabolic functions and sleep.
- MTNR1B gene: Located on chromosome 11, encodes a 362-amino acid GPCR
- Signal transduction: Couples to Gi/o proteins, inhibiting adenylate cyclase and reducing cAMP levels
- Ligand affinity: High affinity for melatonin (Kd ~ 10-100 pM)
- Expression pattern: Species-specific expression patterns in brain and peripheral tissues
- cAMP pathway: Gi/o protein coupling reduces cAMP production
- MAPK pathways: Activates ERK1/2 and p38 MAPK signaling
- Calcium signaling: Modulates intracellular calcium levels
- Gene transcription: Influences clock gene expression through ROR response elements
MTNR1B neurons play essential roles in circadian timekeeping:
-
Phase shifting: Melatonin binding to MT2 receptors shifts circadian phase, particularly during the biological night
-
Sleep promotion: MTNR1B signaling enhances sleep propensity, particularly in the early night
-
Temperature regulation: Melatonin through MT2 receptors modulates body temperature rhythms
-
Hormone secretion: Coordinates rhythmic secretion of other hormones (cortisol, growth hormone)
- Glucose homeostasis: MTNR1B in pancreatic beta cells modulates insulin secretion
- Energy balance: Links circadian timing to metabolic function
- Lipid metabolism: Affects adipocyte function and lipid storage
- Oxidative stress protection: MTNR1B activation reduces oxidative damage
- Mitochondrial function: Enhances mitochondrial biogenesis and function
- Neuroinflammation: Modulates glial activation and inflammatory responses
Genetic variants in MTNR1B are associated with type 2 diabetes risk:
- GWAS findings: MTNR1B variants rs10830963 and rs1387153 increase diabetes risk
- Beta cell dysfunction: Risk variants impair insulin secretion
- Circadian disruption: Diabetes risk may relate to altered circadian glucose regulation
- Obesity: MTNR1B variants linked to BMI and obesity risk
- Metabolic syndrome: Altered melatonin signaling contributes to metabolic dysfunction
- Chrononutrition: Timing of food intake interacts with MTNR1B function
- Circadian disruption: Common in AD patients, may involve MTNR1B dysfunction
- Amyloid regulation: Melatonin through MT2 receptors may affect amyloid processing
- Sleep disturbances: MTNR1B-targeted therapies may improve sleep in AD
- Circadian dysfunction: PD patients show circadian rhythm disturbances
- MT2 receptor changes: Altered MTNR1B expression in PD models
- Neuroprotection: Melatonin receptor activation may protect dopaminergic neurons
- Circadian rhythm sleep disorders: MTNR1B dysfunction may contribute to CRSD
- Shift work disorder: MTNR1B variants affect adaptation to shift work
- Sleep timing: MTNR1B influences preferred sleep timing (chronotype)
- Ramelteon: FDA-approved MT1/MT2 agonist for insomnia
- Agomelatine: MT1/MT2 agonist with antidepressant effects
- Tasimelteon: Approved for non-24-hour sleep-wake disorder
- MTNR1B antagonists: Being explored to improve insulin secretion
- Chronotherapy: Optimizing treatment timing based on circadian biology
- Melatonin supplementation: Being investigated for AD and PD
- MT2-selective compounds: Targeted neuroprotective therapies
- Combination approaches: Melatonin with other circadian modulators
- Liu et al., MTNR1B and type 2 diabetes (2019)
- Dubocovich et al., Melatonin receptors (2018)
- Hardeland et al., Melatonin and neurodegeneration (2019)
- Peschel et al., MTNR1B and circadian rhythms (2019)
- Benarroch, Suprachiasmatic nucleus and melatonin (2018)
- Weaver et al., Melatonin in metabolic diseases (2020)
- Claustrat et al., Melatonin and neurological disorders (2019)
- Tosini et al., Melatonin and retinal function (2020)